Innogen Pharmaceutical

About Innogen Pharmaceutical

Guangzhou Innogen Pharmaceutical Group Co. Ltd. is a clinical-stage biotechnology company focused on developing therapies for metabolic diseases. Founded in 2015 by Dr. Qinghua Wang, a tenured professor from the University of Toronto, the company operates primarily in China with a strategy to address the growing market for diabetes and obesity treatments. Dr. Wang, an expert in diabetes research, returned to China in 2014 and established Innogen to develop innovative drugs, leveraging his extensive background which includes a role on the executive board of the Banting & Best Diabetes Center.

Innogen's business model is centered on the discovery, development, and commercialization of innovative therapies. The company gained significant attention with its core product, Efsubaglutide Alfa (brand name: Diabegone or Yinuoqing), a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. This drug received biologics license application approval from China's National Medical Products Administration (NMPA) in early 2025 for treating type 2 diabetes. The company is also advancing Efsubaglutide Alfa through late-stage trials for obesity and metabolic dysfunction-associated steatohepatitis (MASH). The business strategy relies on differentiation by targeting MASH, pursuing cost leadership, and achieving regulatory agility, including inclusion in China's national reimbursement drug list (NRDL) to boost market access.

The company operates in the highly competitive GLP-1 market in China, which is projected to grow significantly. To fund its pipeline and commercialization efforts, Innogen has raised substantial capital, including a Series A round of $120 million in December 2021 and a subsequent Hong Kong IPO in August 2025 that raised approximately $86 million. The company is publicly held and trades on the Hong Kong Stock Exchange. Its pipeline includes several other drug candidates in preclinical stages for conditions like Alzheimer's disease and fatty liver disease.